Column Group LLC Makes New Investment in Surrozen, Inc. (NASDAQ:SRZNW)

Column Group LLC acquired a new stake in shares of Surrozen, Inc. (NASDAQ:SRZNWFree Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 810,088 shares of the company’s stock, valued at approximately $8,870,000. Surrozen comprises about 12.4% of Column Group LLC’s portfolio, making the stock its 3rd largest holding.

Surrozen Stock Performance

NASDAQ SRZNW opened at $0.02 on Friday. The firm’s 50 day moving average price is $0.01 and its two-hundred day moving average price is $0.02. Surrozen, Inc. has a twelve month low of $0.01 and a twelve month high of $0.11.

About Surrozen

(Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Read More

Want to see what other hedge funds are holding SRZNW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surrozen, Inc. (NASDAQ:SRZNWFree Report).

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.